Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence

摘要

The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent. The aim of the invention is to develop a new pharmaceutical agent with minimal side effects. The proposed therapeutic substance, for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which is presented by polyprenols of formula (1)
where n = 8-20. Therapeutic composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in patients is suggested, which includes an effective amount of polyprenols of formula (1)
where n = 8-20.
and pharmaceutically acceptable excipients, including carriers, and/or solvents. Pharmaceutical composition may be executed in the form of a solution, suspension, capsule, tablet, liposome form. Attached is the use of polyprenols of formula (1)
where n = 8-20
as an active ingredient of the pharmaceutical composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients. Attached is the method of treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which differs in that it includes administration of polyprenols of formula (1). From the above-mentioned results of the study of the therapeutic substance based on compound of formula (1) conducted in the clinic, one is able to conclude the efficacy of the treatment for addiction to ethyl alcohol and/or drugs, on recovering of abstinence syndrome, and on the improvement of psychosomatic state in patients, as well as on significant improvement of neurological disorders and/or complete regression of polyneuropathy. It is important to note, that Ropren is well tolerated by patients and side effects, allergic reactions and impairments were not found in any patient in the experimental group for the whole period of treatment.